Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor Ad hoc announcement pursuant to Art. 53...
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value Ad hoc announcement pursuant to...
Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call Idorsia will publish its Full Year 2023...
Bondholders approve amended terms of the 2024 convertible bonds Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of...
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond Ad hoc announcement pursuant to Art...
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension Ad hoc announcement pursuant to Art. 53 LR...
Idorsia publishes an invitation to a bondholder meeting Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6...
Idorsia publishes a Financial Status required for an upcoming bondholder meeting Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
